| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Assessment of Juvenile Pigs to Serve as Human Pediatric Surrogates for Preclinical Formulation Pharmacokinetic Testing
|
Roth, Wyatt J.
|
|
2013
|
15 |
3 |
p. 763-774
|
article
|
| 2 |
Bioequivalence for Locally Acting Nasal Spray and Nasal Aerosol Products: Standard Development and Generic Approval
|
Li, Bing V.
|
|
2013
|
15 |
3 |
p. 875-883
|
article
|
| 3 |
CDER Risk Assessment Exercise to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products
|
Cruz, Celia N.
|
|
2013
|
15 |
3 |
p. 623-628
|
article
|
| 4 |
Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (Promptol™)—Application of a New “Physiologically Based” Model to Assess Absorption and Disposition
|
Wang, Yanfeng
|
|
2013
|
15 |
3 |
p. 787-796
|
article
|
| 5 |
Comparative In Silico–In Vivo Evaluation of ASGP-R Ligands for Hepatic Targeting of Curcumin Gantrez Nanoparticles
|
D’Souza, Anisha A.
|
|
2013
|
15 |
3 |
p. 696-706
|
article
|
| 6 |
Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia
|
Fetterly, Gerald J.
|
|
2013
|
15 |
3 |
p. 662-673
|
article
|
| 7 |
Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
|
Prueksaritanont, Thomayant
|
|
2013
|
15 |
3 |
p. 629-645
|
article
|
| 8 |
Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates
|
Bonate, Peter L.
|
|
2013
|
15 |
3 |
p. 832-839
|
article
|
| 9 |
Engineered Mannitol Ternary Additives Improve Dispersion of Lactose–Salbutamol Sulphate Dry Powder Inhalations
|
Kaialy, Waseem
|
|
2013
|
15 |
3 |
p. 728-743
|
article
|
| 10 |
Epigenetic Modifications of Nrf2 by 3,3′-diindolylmethane In Vitro in TRAMP C1 Cell Line and In Vivo TRAMP Prostate Tumors
|
Wu, Tien-Yuan
|
|
2013
|
15 |
3 |
p. 864-874
|
article
|
| 11 |
Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics
|
Xue, Li
|
|
2013
|
15 |
3 |
p. 893-896
|
article
|
| 12 |
Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development
|
Chimalakonda, Anjaneya P.
|
|
2013
|
15 |
3 |
p. 717-727
|
article
|
| 13 |
Generic Development of Topical Dermatologic Products, Part II: Quality by Design for Topical Semisolid Products
|
Chang, Rong-Kun
|
|
2013
|
15 |
3 |
p. 674-683
|
article
|
| 14 |
Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment
|
Thway, Theingi M.
|
|
2013
|
15 |
3 |
p. 856-863
|
article
|
| 15 |
Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies
|
Parra-Guillen, Zinnia P.
|
|
2013
|
15 |
3 |
p. 797-807
|
article
|
| 16 |
Molecular Mechanisms of Silibinin-Mediated Cancer Chemoprevention with Major Emphasis on Prostate Cancer
|
Ting, Harold
|
|
2013
|
15 |
3 |
p. 707-716
|
article
|
| 17 |
Non-Arrhenius Protein Aggregation
|
Wang, Wei
|
|
2013
|
15 |
3 |
p. 840-851
|
article
|
| 18 |
Nonlinear Absorption Kinetics of Self-Emulsifying Drug Delivery Systems (SEDDS) Containing Tocotrienols as Lipophilic Molecules: In Vivo and In Vitro Studies
|
Alqahtani, Saeed
|
|
2013
|
15 |
3 |
p. 684-695
|
article
|
| 19 |
Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids
|
Gao, Yue
|
|
2013
|
15 |
3 |
p. 816-831
|
article
|
| 20 |
Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical Scientists
|
Xue, Li
|
|
2013
|
15 |
3 |
p. 852-855
|
article
|
| 21 |
Protective Effects of Kaempferol on Isoniazid- and Rifampicin-Induced Hepatotoxicity
|
Shih, Tung-Yuan
|
|
2013
|
15 |
3 |
p. 753-762
|
article
|
| 22 |
Resveratrol Suppresses T0901317-Induced Hepatic Fat Accumulation in Mice
|
Gao, Mingming
|
|
2013
|
15 |
3 |
p. 744-752
|
article
|
| 23 |
Risk Assessment of Drug Interaction Potential and Concomitant Dosing Pattern on Targeted Toxicities in Pediatric Cancer Patients
|
Barrett, Jeffrey S.
|
|
2013
|
15 |
3 |
p. 775-786
|
article
|
| 24 |
Sequential Bioequivalence Trial Designs with Increased Power and Controlled Type I Error Rates
|
Fuglsang, Anders
|
|
2013
|
15 |
3 |
p. 659-661
|
article
|
| 25 |
Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation
|
Kelley, Marian
|
|
2013
|
15 |
3 |
p. 646-658
|
article
|
| 26 |
Utilization of Gene Expression Signature for Quality Control of Traditional Chinese Medicine Formula Si-Wu-Tang
|
Xie, Chen
|
|
2013
|
15 |
3 |
p. 884-892
|
article
|
| 27 |
What is the Likelihood of an Active Compound to Be Promiscuous? Systematic Assessment of Compound Promiscuity on the Basis of PubChem Confirmatory Bioassay Data
|
Hu, Ye
|
|
2013
|
15 |
3 |
p. 808-815
|
article
|
Journal description